Avalon's latest biotech closes $58M round as it pursues treatments for autoimmune brain conditions
Arialys Therapeutics announced Tuesday that it tied the bow on a $58 million seed round to develop treatments specifically for brain disorders caused by immune reactions.
Endpoints News reported in December that the CNS biotech was working on a $55 million round, which was backed by Avalon BioVentures, MPM Capital and Catalys Pacific. Johnson & Johnson’s venture capital arm and Alexandria Venture Investments also took part in the big seed round.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.